---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-23-000038"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T05:19:20.709988+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q3 2023 revenues up 12% to $919M; Jakafi guidance tightened to $2.59-2.62B

## Summary
- Total GAAP revenues of $919M (+12% YoY); GAAP net income $171M ($0.76 diluted EPS).
- Jakafi net product revs $636M (+3% YoY); Opzelura $92M (+141% YoY) on AD/vitiligo demand.
- Non-GAAP diluted EPS $1.10 vs $0.60 in Q3 2022; operating income up 63% to $273M.
- FY 2023 Jakafi guidance tightened to $2.59-2.62B from $2.58-2.63B; other guidance unchanged.
- Phase 2 povorcitinib in prurigo nodularis met primary endpoint; Phase 3 planned for 2024.

## SEC filing metadata
- accession: 0000879169-23-000038
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916923000038/0000879169-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916923000038/incy-20231031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-23-000038
- JSON: https://secwatch.observer/filing/0000879169-23-000038.json
- Plain text: https://secwatch.observer/filing/0000879169-23-000038.txt

## Key facts
- Earnings Releases
  INCYTE CORP reported third fiscal quarter ended September 30, 2023 results: revenue $919 million. Guidance reaffirmed.
  - Period: third fiscal quarter ended September 30, 2023
  - Revenue: $919 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $919 million in the third quarter (Q3'23)
  evidence_url: https://www.sec.gov/Archives/edgar/data/879169/000087916923000038/0000879169-23-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.